GlaxoSmithKline has paid £146 million for Basilea Pharmaceutica’s dermatology drug Toctino. Toctino (alitretinoin) is approved for the treatment of adults …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

